Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Opdated results of the phase III keynote-048 study

by Harrington, Kevin J., Burtness, Barbara, Greil, Richard, Soulieres, Denis, Tahara, Makoto, de Castro Jr, Gilberto, Psyrri, Amanda, Brana, Irene, Baste, Neus, Neupane, Prakash, Bratland, Ase, Fuereder, Thorsten, Hughes, Brett G. M., Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Lin, Jianxin, Gumuscu, Burak, Swaby, Ramona F., Rischin, Danny
Published 2023

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis

by Benner, Axel, Mansouri, Larry, Rossi, Davide, Majid, Aneela, Willander, Kerstin, Parker, Anton, Bond, Gareth, Pavlova, Sarka, Nückel, Holger, Merkel, Olaf, Ghia, Paolo, Montserrat, Emili, Kaderi, Mohd Arifin, Rosenquist, Richard, Gaidano, Gianluca, Dye, Martin J.S., Söderkvist, Peter, Linderholm, Mats, Oscier, David, Tvaruzkova, Zuzana, Pospisilova, Sarka, Dührse, Ulrich, Greil, Richard, Döhner, Hartmut, Stilgenbauer, Stephan, Zenz, Thorsten
Published 2014

Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048

by Rischin, Danny, Harrington, Kevin J., Greil, Richard, Soulieres, Denis, Tahara, Makoto, de Castro Jr, Gilberto, Psyrri, Amanda, Brana, Irene, Neupane, Prakash, Bratland, Ase, Fuereder, Thorsten, Hughes, Brett G. M., Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Ishak, Wan Zamaniah Wan, Hong, Ruey-Long, Mendoza, Rene Gonzalez, Jia, Liyi, Chirovsky, Diana, Norquist, Josephine, Jin, Fan, Burtness, Barbara
Published 2022